Previous data confirmed 32.1% KRAS mutation lung adenocarcinoma in our country, which is within the average (25%–35%) of other observations.25, 26 In our ILD patients with lung adenocarcinoma four patients (31%) were harboring the KRAS mutation, three had UIP and one CTD‐ILD. Here, KRAS is linked to interstitial lung disease.